BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target

Benzinga Newsdesk www.benzinga.com Positive 68.0%

Neg 0% Neu 0% Pos 68%

BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.